GSK3B and colonic neoplasm: This mechanism has been demonstrated previously in colon cancer cell lines, and it occurs in tumors where the GSK3β activator (Tyr216 pGSK3β) and inhibitor (Ser9 pGSK3β) are in disbalance, with Tyr216 pGSK3β acting as an oncogene [28].